Methods for nuclear reprogramming of cells

Patent metadata

Field	Value
Publication number	US-11976303-B2
Application number	US-202016994336-A
Country	US
Kind code	B2
Filing date	Aug 14, 2020
Priority date	Sep 20, 2013
Publication date	May 7, 2024
Grant date	May 7, 2024

Abstract

Described herein are methods for enhancing the nuclear reprogramming of somatic cells to become induced pluripotent stem cells. In particular, the methods disclosed herein involve the use of damage-associated molecular pattern molecules (DAMP). In certain embodiments the DAMPs are aluminum compositions such as aluminum hydroxide. Such DAMPs have unexpectedly and surprisingly been found to enhance the nuclear reprogramming efficiency of the reprogramming factors commonly used to induce somatic cells to become induced pluripotent stem cells. Accordingly, this disclosure describes methods of nuclear reprogramming as well as cells obtained from such methods along with therapeutic methods for using such cells for the treatment of disease amendable to treatment by stem cell therapy; as well as kits for such uses.

First claim

What is claimed is:

1. An in vitro method of enhancing nuclear reprogramming of a human somatic cell, the method comprising: contacting a population of-human somatic cells with (a) an effective dose of an aluminum composition; and (b) a cocktail of reprogramming factors; for a period of time sufficient to reprogram the human somatic cells to induced pluripotent stem cells, wherein the aluminum composition is selected from the group consisting of aluminum hydroxide, aluminum phosphate and aluminum sulfate.

2. The method of claim 1 , wherein the aluminum composition and reprogramming factors are provided sequentially or simultaneously.

3. The method of claim 1 , wherein the aluminum composition is aluminum hydroxide.

4. The method of claim 3 , wherein the effective dose of aluminum hydroxide is about or at least 40-80 micrograms/ml.

5. The method of claim 1 , wherein the aluminum composition is aluminum phosphate.

6. The method of claim 1 , wherein the aluminum composition is aluminum sulfate.

7. The method of claim 1 , wherein the cocktail of reprogramming factors comprises the use of nucleic acids encoding Oct4, Sox2, Lin28, and Nanog, or corresponding cell permeant peptides of the same, and the cells are reprogrammed to pluripotency.

8. The method of claim 1 , wherein the cocktail of reprogramming factors comprises the use of nucleic acids encoding Oct4, Sox2, c-Myc, and KLF4, or corresponding cell permeant peptides of the same, and the cells are reprogrammed to pluripotency.

9. The method of claim 1 , wherein the human somatic cell type is peripheral blood mononuclear cell (PBMC), cord blood mononuclear cells, or fibroblasts.

10. The method of claim 1 , wherein the reprogramming factors are provided as cell permeant proteins.

11. The method of claim 1 , wherein the reprogramming factors are provided as nucleic acids encoding the proteins.

12. The method of claim 1 , resulting in a nuclear reprogramming efficiency wherein the nuclear reprogramming efficiency is greater than if the method was carried out without the aluminum composition.

13. The method of claim 12 wherein the nuclear reprogramming efficiency is about 1 to about 5 fold greater with respect to the expression of at least one key pluripotency marker.

14. The method of claim 12 wherein the nuclear reprogramming efficiency is about 1 to about 5 fold greater with respect to an amount of the induced pluripotent stem cells produced.

Assignees

• Lonza Ag

Inventors

• Walsh Patrick
• Fellner Thomas

Classifications

• C12N5/0696 Primary

  Artificially induced pluripotent stem cells, e.g. iPS · CPC title

• A61K33/08

  Oxides; Hydroxides · CPC title

• C12N2500/12

  Light metals, i.e. alkali, alkaline earth, Be, Al, Mg · CPC title

• C12N2500/90

  Serum-free medium, which may still contain naturally-sourced components · CPC title

• C12N2506/11

  from blood or immune system cells · CPC title